Zhengye Biotechnology Holding (ZYBT) Liabilities and Shareholders Equity (2023 - 2025)
Zhengye Biotechnology Holding has reported Liabilities and Shareholders Equity over the past 3 years, most recently at $61.5 million for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 10.38% to $61.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $269.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $60.7 million for FY2025, 10.12% down from the prior year.
- Liabilities and Shareholders Equity was $61.5 million for Q4 2025 at Zhengye Biotechnology Holding, down from $69.8 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $69.8 million in Q2 2025 and troughed at $61.5 million in Q4 2025.
- The 3-year median for Liabilities and Shareholders Equity is $69.0 million (2024), against an average of $67.4 million.
- Year-over-year, Liabilities and Shareholders Equity decreased 1.1% in 2024 and then dropped 10.38% in 2025.
- A 3-year view of Liabilities and Shareholders Equity shows it stood at $69.4 million in 2023, then decreased by 1.1% to $68.7 million in 2024, then decreased by 10.38% to $61.5 million in 2025.
- Per Business Quant, the three most recent readings for ZYBT's Liabilities and Shareholders Equity are $61.5 million (Q4 2025), $69.8 million (Q2 2025), and $68.7 million (Q4 2024).